Small-business device fee relief comes with hidden tariff on imports

What it does

This bill amends the Federal Food, Drug, and Cosmetic Act to expand the small business waiver from FDA device registration fees. It redefines 'small business' as entities with fewer than 20 full-time employees (down from a higher threshold), grants a 3-year 100% fee waiver followed by a 2-year 50% waiver to qualifying small businesses, and bars foreign-owned companies from claiming the waiver while imposing an 8× fee multiplier on foreign establishments. The bill also prohibits the FDA from considering past non-payment when evaluating waiver eligibility.

Why we flagged it

The bill's core mechanism is a cost waiver for small domestic device manufacturers—a regulatory relief measure. However, the 8× fee on foreign competitors and the non-reviewability clause suggest a secondary protectionist and accountability-limiting intent that extends beyond simple small-business support.

• Section 3 imposing 8× fee multiplier on foreign establishments is substantively unrelated to small-business fee relief and functions as a tariff-like trade barrier.

What the text implies

• The 8× fee on foreign device manufacturers may increase import costs, potentially raising prices for consumers dependent on foreign-sourced medical devices and reducing competition in the U.S. market.
• The non-reviewability clause (Section 2(5)) removes judicial review of FDA waiver denials, preventing small businesses from challenging arbitrary or discriminatory denials in court.

The full analysis lists 5 implications of this text.

Who stands to gain

small domestic medical device manufacturers; small domestic in vitro diagnostic manufacturers; domestic device startups and emerging competitors